VEGFA and age-related macular degeneration: Despite intense investigational efforts in the field of AMD and the approval of Pegcetacoplan in early 2023 as the first therapy for late-stage dry AMD7, the knowledge on the exact pathophysiology still remains incomplete and we still lack effective treatments for earlier stages of AMD that have the potential to prevent irreversible visual impairment altogether, whereas anti-VEGF therapy is available for the exudative form of AMD8,9.